INCY•benzinga•
Incyte Announced Topline Results From Its Phase 3 STOP-HS Clinical Trial Program Of Povorcitinib For Severe Hidradenitis Suppurativa, Both STOP-HS1 And STOP-HS2 Studies Met Their Primary Endpoint At Both Tested Doses
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 17, 2025 by benzinga